What happens to the powder before it becomes a medicine

A component is more than what ends up in the vial

The manufacturing rules define their own vocabulary, and the definition of a component is wider than it sounds.

A component is any ingredient intended for use in the manufacture of a drug product, including those that may not appear in such drug product.

That last clause is the interesting one. A solvent used during preparation and removed afterward is still a component, and so is anything that reacts away during the chemistry. The rules follow the material, not the ingredient list.

The subpart that governs those materials is written as procedures rather than as outcomes. There have to be written procedures describing, in sufficient detail, the receipt, identification, storage, handling, sampling, testing, and approval or rejection of components.

Seven activities are named in that one sentence, and only two of them are laboratory work. The rest happen in a room with a pallet in it.

The first thing that happens is a look, not a test

Upon receipt and before acceptance, each container or grouping of containers has to be examined visually. The rule names what the examination is for.

Appropriate labeling as to contents. Container damage or broken seals. Contamination.

None of that is analytical chemistry, and none of it needs a laboratory. It is somebody checking that the drum says what it should say, that it is intact, and that nothing has gotten into it.

It matters because it is the only check that can catch a problem the laboratory will never see. A correct assay on material from a compromised container is a true result about a sample and a misleading result about the shipment.

Whether the contents are what the label claims is a separate question, answered by testing. A companion article on this site covers that system and the conditions attached to relying on somebody else's certificate.

Nothing is available until it is released

Components are stored under quarantine until they have been tested or examined, whichever is appropriate, and released.

Quarantine here is a status rather than a room, and the phrase whichever is appropriate is doing real work. Some material is tested and some is examined, depending on what the material is. Either way, arrival is not the same thing as availability.

Storage during that period still has to meet the general requirements, so quarantined material is not parked outside the system while it waits.

The parallel on the other end of the process is exact. Finished product is also quarantined before release, and a separate article on returned and salvaged product covers that side.

Every lot gets a code, and the code is the trail

Each container or grouping of containers is identified with a distinctive code for each lot in each shipment received.

The rule then says what the code is for. It is used in recording the disposition of each lot.

And each lot has to be identified as to its status, which the regulation spells out in three words: quarantined, approved, or rejected.

That is a labeling requirement with a records requirement hidden inside it. A code that appears on a drum and nowhere else proves nothing. A code that appears on the drum and in the disposition record is what makes a batch answerable later.

One point of confusion is worth clearing up. A different section requires major equipment to carry a distinctive identification code, and that code identifies a machine. This one identifies a lot of incoming material. Both phrases appear in the same part, and they point at different objects.

Off the floor, spaced, and handled to prevent contamination

Two short requirements govern the physical handling, and both are more specific than a general instruction to be careful.

Components and drug product containers and closures have to be handled and stored at all times in a manner to prevent contamination.

Bagged or boxed material has to be stored off the floor and suitably spaced to permit cleaning and inspection.

The reason for the spacing is stated in the rule itself. It is so the area can be cleaned and so the material can be inspected. A pallet pushed against a wall defeats both.

This is the plainest sentence in the subpart, and it is a useful reminder of what these rules actually are. They are mostly about ordinary warehouse discipline, written down and made auditable.

Oldest first, on the way in as well as the way out

Approved components, containers and closures have to be rotated so that the oldest approved stock is used first.

Deviation is permitted on two conditions stated together: that it is temporary, and that it is appropriate.

Readers of the article on returned product will recognize the sentence, because the same rule appears in the distribution subpart for finished goods. The manufacturing rules apply the principle at both ends.

The effect on the buyer is indirect but real. Material that sits gets used before material that arrived yesterday, which is what stops the oldest stock aging quietly at the back of a shelf.

Approved is not permanent

This is the requirement most often missing from a quality claim, and it is one sentence long.

Components, containers and closures have to be retested or reexamined, as appropriate, for identity, strength, quality and purity, and approved or rejected by the quality control unit, as necessary.

The rule then gives its own examples of when. After storage for long periods. After exposure to air, heat or other conditions that might adversely affect the material.

So a release decision has a shelf life of its own. A certificate that was accurate on the day it was issued describes material in the condition it was in that day.

For a temperature-sensitive starting material this is the whole point. A separate article covers what storage does to a peptide chemically, and this rule is the paperwork counterpart of that chemistry.

Rejected material gets a quarantine of its own

Rejected components, containers and closures have to be identified and controlled under a quarantine system.

The regulation states what that system is designed to do. It prevents their use in manufacturing or processing operations for which they are unsuitable.

Read the last clause of that sentence closely. It is not a blanket ban on ever using the material again. It is a ban on using it where it does not belong, which is why the control is a system rather than a bin.

The same structure appears later in the part for in-process material that fails, and an article on this site covers that stage.

The record that ties a drum to a vial

The records subpart says what has to be written down about all of this, and the list is longer than most people expect.

For each shipment of each lot: the identity and quantity, the name of the supplier, the supplier's lot numbers if known, the receiving code, and the date of receipt.

One more field sits at the end of that sentence. The name and location of the prime manufacturer, if different from the supplier, has to be listed if known.

That is the rule's acknowledgment that the company selling a material is often not the company that made it. It is also conditional twice over, on difference and on knowledge.

Then comes the field that makes the whole trail useful. There has to be an individual inventory record for each component, with a reconciliation of the use of each lot.

The regulation states the standard that record has to meet. It must contain sufficient information to allow determination of any batch or lot of drug product associated with the use of each component.

That sentence is the reason any of the handling rules matter. If a starting material turns out to be wrong, the records are supposed to answer which finished lots it went into. The disposition of rejected components is a required field too.

Who these rules bind, and what a reader can do with them

The regulation states its own reach. It contains the minimum current good manufacturing practice for preparation of drug products for administration to humans or animals.

Whether a given compounder is held to it depends on which part of the compounding statute that facility operates under, because the two categories are exempted from different lists of requirements. That comparison is the subject of the article on what a compounding exemption actually exempts.

So this is a reference point rather than a promise about any seller. It describes what handling looks like when somebody is required to document it.

Three questions for a reader come out of it. Does a quality claim describe testing only, since testing is two of seven named activities. Does anything on the page name the maker of the starting material rather than the seller of it. And does the claim say anything about how long ago the material was released, since approval is a dated decision rather than a permanent state.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. Title 21 Code of Federal Regulations Section 211.80, General requirements, read in full including the written procedures covering receipt, identification, storage, handling, sampling, testing and approval or rejection, the storage of bagged or boxed material off the floor and suitably spaced to permit cleaning and inspection, and the distinctive code identifying each lot in each shipment together with its quarantined, approved or rejected status — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026
2. Title 21 Code of Federal Regulations Section 211.82, Receipt and storage of untested components, drug product containers, and closures, requiring visual examination on receipt and before acceptance for appropriate labeling as to contents, container damage or broken seals, and contamination, and quarantine storage until tested or examined and released — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026
3. Title 21 Code of Federal Regulations Section 211.86, Use of approved components, drug product containers, and closures, requiring rotation so that the oldest approved stock is used first and permitting deviation only where it is temporary and appropriate — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026
4. Title 21 Code of Federal Regulations Section 211.87, Retesting of approved components, drug product containers, and closures, requiring retesting or reexamination for identity, strength, quality and purity as necessary, with the examples of storage for long periods and exposure to air, heat or other conditions that might adversely affect the material — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026
5. Title 21 Code of Federal Regulations Section 211.89, Rejected components, drug product containers, and closures, requiring that rejected material be identified and controlled under a quarantine system designed to prevent its use in operations for which it is unsuitable — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026
6. Title 21 Code of Federal Regulations Section 211.184, Component, drug product container, closure, and labeling records, requiring the identity and quantity of each shipment, the supplier name, the supplier lot numbers if known, the receiving code, the date of receipt, the prime manufacturer if different and known, an individual inventory record with a reconciliation of each lot, and the disposition of rejected material — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026
7. Title 21 Code of Federal Regulations Section 210.3, Definitions, whose definition of a component reaches any ingredient intended for use in the manufacture of a drug product including those that may not appear in it — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026
8. Title 21 Code of Federal Regulations Section 211.1, Scope, stating that the part contains the minimum current good manufacturing practice for preparation of drug products for administration to humans or animals — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026